Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.
The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes. Imetelstat works by directly binding to the RNA template of telomerase, thereby blocking the enzyme’s activity and shortening telomeres in malignant cells. Preclinical studies have also explored potential applications of telomerase inhibition in various solid tumors.
Founded in 1990 by researchers Elizabeth Blackburn, Carol Greider and Jack Szostak—who later received the Nobel Prize in Physiology or Medicine for their work on telomeres—Geron is headquartered in Foster City, California. The company has established collaborations and licensing agreements with academic institutions, contract research organizations and pharmaceutical partners to advance its clinical programs and expand its research capabilities.
Under the leadership of CEO John A. Scarlett, Geron continues to build its infrastructure for late-stage clinical development. The company serves a global community of physicians, researchers and patients by conducting multi-center clinical trials across North America and Europe, with the goal of bringing telomerase-targeted therapies to market.
AI Generated. May Contain Errors.
